A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.
A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.
Preliminary research studies have shown that patients with Hodgkin lymphoma may overexpress the programmed death ligand-1 (PD-1) protein on their cell surface, indicating that the tumors may be dependent on PD-1 for survival, and thus making it an ideal drug target. To test this hypothesis, the KEYNOTE-013 trial enrolled 31 patients with relapsed, refractory Hodgkin lymphoma who had progressed following treatment with brentuximab vedotin. Patients were treated with pembrolizumab every 2 weeks until week 12, and every 8 weeks after, until disease progression. Safety and complete remission (CR) rate were the primary trial endpoints.
Of the 31 patients, 55% had had more than 4 lines of therapy and 71% had relapsed following autologous stem cell transplant. The observed CR rate was 16% (90% CI, 7% to 31%). Nearly half (48%) the patients achieved a partial remission for an overall response rate of 65% (90% CI, 48% to 79%). A majority (70%) of the responses lasted for more than 6 months, with a median follow-up of 17 months.
The most commonly observed adverse events (AEs) were hypothyroidism (16%), diarrhea (16%), nausea (13%), and pneumonitis (10%). Grade 3 AEs were observed in 16% of patients, namely colitis, increased ALT and AST levels, nephrotic syndrome, joint swelling, back pain, and axillary pain. There were no grade 4 treatment-related AEs.
The authors feel that their results are a sufficient prerogative for further studies of pembrolizumab in patients with Hodgkin lymphoma.
The study is published in the November issue of the Journal of Clinical Oncology.
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
November 30th 2023Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Read More
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More